Virbac and TransAlgae have signed a cooperation agreement
TransAlgae which aims to shape the future of vaccination in the field of aquaculture with its disruptive microalgae-based oral delivery technology is proud to announce the finalization and signing of an exclusive business development collaboration agreement with Virbac, a French company and one of the leading animal health players worldwide. Virbac was founded more than fifty years ago and is today the sixth-largest animal health company worldwide, with 33 subsidiaries and a presence in more than 100 countries. Virbac has acted under the banner of innovation to deliver a practical range of products and services to diagnose, prevent and treat the majority of pathologies, all while improving the quality of life for animals. The companies have signed an exclusive collaboration agreement to develop a vaccine based on TransAlgae's break-through technology and are engaged together in a long term business relationship.